224 related articles for article (PubMed ID: 25229619)
1. Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery.
Leil TA; Frost C; Wang X; Pfister M; LaCreta F
CPT Pharmacometrics Syst Pharmacol; 2014 Sep; 3(9):e136. PubMed ID: 25229619
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Imberti D; Gallerani M; Manfredini R
J Thromb Thrombolysis; 2012 Aug; 34(2):208-13. PubMed ID: 22466929
[TBL] [Abstract][Full Text] [Related]
4. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
[TBL] [Abstract][Full Text] [Related]
5. The role of apixaban for venous and arterial thromboembolic disease.
Prom R; Spinler SA
Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
[TBL] [Abstract][Full Text] [Related]
6. Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain.
Granero Xiberta X; Murcia A; Troncoso Durán JR; Gómez Zubeldia C; Llorac Moix A; Graefenhain De Codes R; Ferrario MG; Lizán L
J Health Econ Outcomes Res; 2016; 4(1):35-46. PubMed ID: 34430666
[No Abstract] [Full Text] [Related]
7. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
Mahmoudi M; Sobieraj DM
Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
[TBL] [Abstract][Full Text] [Related]
9. Risk of gastrointestinal bleeding in patients undergoing total hip or knee replacement compared with matched controls: a nationwide cohort study.
Lalmohamed A; Vestergaard P; Javaid MK; de Boer A; Leufkens HG; van Staa TP; de Vries F
Am J Gastroenterol; 2013 Aug; 108(8):1277-85. PubMed ID: 23629603
[TBL] [Abstract][Full Text] [Related]
10. Physiotherapy rehabilitation after total knee or hip replacement: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(8):1-91. PubMed ID: 23074477
[TBL] [Abstract][Full Text] [Related]
11. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.
Stanifer JW; Pokorney SD; Chertow GM; Hohnloser SH; Wojdyla DM; Garonzik S; Byon W; Hijazi Z; Lopes RD; Alexander JH; Wallentin L; Granger CB
Circulation; 2020 Apr; 141(17):1384-1392. PubMed ID: 32160801
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Burness CB; McKeage K
Drugs; 2012 May; 72(7):963-86. PubMed ID: 22564134
[TBL] [Abstract][Full Text] [Related]
13. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
[TBL] [Abstract][Full Text] [Related]
14. Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis.
Caldeira D; Rodrigues FB; Pinto FJ; Ferreira JJ; Costa J
Clin Med Insights Blood Disord; 2017; 10():1179545X17704660. PubMed ID: 28579855
[TBL] [Abstract][Full Text] [Related]
15. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
Lu X; Lin J
BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
[TBL] [Abstract][Full Text] [Related]
16. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
17. Thromboprophylaxis with apixaban and the risk of pulmonary embolism in patients undergoing knee replacement surgery.
Aryal MR; Pandit A; Ghimire S; Pathak R; Karmacharya P; Poudel DR; Shamoun FE
J Community Hosp Intern Med Perspect; 2015; 5(4):27889. PubMed ID: 26333856
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment.
Pathak R; Pandit A; Karmacharya P; Aryal MR; Ghimire S; Poudel DR; Shamoun FE
Am J Cardiol; 2015 Feb; 115(3):323-7. PubMed ID: 25527282
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
